Germany's Saltigo to manufacture novel drug pipeline product for Daiichi Sankyo
German custom manufacturing specialist Saltigo GmbH, a subsidiary of Lanxess (Xetra: LXS), has signed a deal with Japanese drug major Daiichi Sankyo (TYO: 4568) to provide contract manufacturing service.
Saltigo, which achieved total sales in 2012 of 1,674 million euros ($2.1 million) signed the agreement in Tokyo in preparation for the commercialization of one of Daiichi Sankyo’s novel drug pipeline projects.
Wolfgang Schmitz, managing director of Saltigo, said: “Daiichi Sankyo is one of the largest pharma players in the second largest pharma market in the world and decided to work with a globally-recognized CMO-partner such as our company. It is a great honor for Saltigo to enter into this agreement with Daiichi Sankyo and we look forward to the continuation and further proactive development of our business relationship.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze